The National Institute for Health and Clinical Excellence will face a judicial review into its decision to restrict access on the NHS to three dementia drugs at the High Court from 25 June.
The healthcare advisory body had ruled that three drugs, Aricept, Exelon and Reminyl, should no longer be available for people with mild or severe dementia, but drugs companies Eisai and Pfizer successfully persuaded the court to grant a review, the first into a Nice decision.
The hearing has been scheduled for four days.
Previous articles:
Alzheimer’s Society takes drugs storm to High Court
New guidance out as drug ruling bites
Alzheimer’s drug appeal rejected
Bournemouth, Christchurch and Poole 
Hampshire County Council 
Lincolnshire County Council 
Norfolk County Council 
Northamptonshire Children’s Trust 
South Gloucestershire Council 
Wiltshire Council 
Wokingham Borough Council 
Children and young people with SEND are ‘valued and prioritised’ in Wiltshire, find inspectors 
How specialist refugee teams benefit young people and social workers 
Podcast: returning to social work after becoming a first-time parent 
Podcast: would you work for an inadequate-rated service? 
Family help: one local authority’s experience of the model 
‘We are all one big family’: how one council has built a culture of support 
Workforce Insights – showcasing a selection of the sector’s top recruiters 
Facebook
X
LinkedIn
Instagram
Comments are closed.